Anteris Technologies (ASX:AVR) - Stock Price, News & Analysis

AVR Stock Overview

Anteris Technologies Ltd, a structural heart company, designs, develops, and commercializes medical devices.

AVR fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	1/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 10.26% per year

Risk Analysis

Earnings are forecast to decline by an average of 11.2% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Does not have meaningful revenue (A$4M)

Anteris Technologies Ltd Competitors

EBR Systems

ASX:EBR

AU$278.8m

ImpediMed

ASX:IPD

AU$182.1m

Cyclopharm

ASX:CYC

AU$164.8m

Optiscan Imaging

ASX:OIL

AU$71.8m

Price History & Performance

Summary of all time highs, changes and price drops for Anteris Technologies
Historical stock prices
Current Share Price	AU$22.75
52 Week High	AU$24.38
52 Week Low	AU$15.58
Beta	0.75
1 Month Change	-1.94%
3 Month Change	40.52%
1 Year Change	3.03%
3 Year Change	130.96%
5 Year Change	279.17%
Change since IPO	-70.07%

Recent updates

Increases to CEO Compensation Might Be Put On Hold For Now at Anteris Technologies Ltd (ASX:AVR)

Jul 08

Increases to Anteris Technologies Ltd's (ASX:AVR) CEO Compensation Might Cool off for now

May 07

Does Anteris Technologies' (ASX:AVR) CEO Salary Compare Well With The Performance Of The Company?

Feb 21

Anteris Technologies Ltd (ASX:AVR) Insiders Have Been Selling

Dec 10

Shareholder Returns

	AVR	AU Medical Equipment	AU Market
7D	-1.1%	0.3%	0.4%
1Y	3.0%	13.9%	6.0%

Return vs Industry: AVR underperformed the Australian Medical Equipment industry which returned 13.9% over the past year.

Return vs Market: AVR underperformed the Australian Market which returned 6% over the past year.

Price Volatility

Is AVR's price volatile compared to industry and market?
AVR volatility
AVR Average Weekly Movement	4.6%
Medical Equipment Industry Average Movement	10.2%
Market Average Movement	8.9%
10% most volatile stocks in AU Market	17.6%
10% least volatile stocks in AU Market	3.5%

Stable Share Price: AVR's share price has been volatile over the past 3 months.

Volatility Over Time: AVR's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1999	n/a	Wayne Paterson	www.anteristech.com

Anteris Technologies Ltd, a structural heart company, designs, develops, and commercializes medical devices. The company manufactures and sells ADAPT, a regenerative tissue product. Its lead product is the DurAVRTM, a transcatheter heart valve for the treatment of aortic stenosis.

Anteris Technologies Ltd Fundamentals Summary

How do Anteris Technologies's earnings and revenue compare to its market cap?
AVR fundamental statistics
Market cap	AU$441.84m
Earnings (TTM)	-AU$67.33m
Revenue (TTM)	AU$4.11m

106.3x

P/S Ratio

-6.5x

P/E Ratio

Is AVR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AVR income statement (TTM)
Revenue	AU$4.11m
Cost of Revenue	AU$1.59m
Gross Profit	AU$2.52m
Other Expenses	AU$69.85m
Earnings	-AU$67.33m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-3.51
Gross Margin	61.23%
Net Profit Margin	-1,637.85%
Debt/Equity Ratio	0%

How did AVR perform over the long term?

See historical performance and comparison

AVR Stock Overview

Rewards

Risk Analysis

Anteris Technologies Ltd Competitors

ASX:EBR

AU$278.8m

ASX:IPD

AU$182.1m

ASX:CYC

AU$164.8m

ASX:OIL

AU$71.8m

Price History & Performance

Recent News & Updates

Anteris Technologies Ltd, Annual General Meeting, May 29, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 40 million.

First half 2023 earnings released: AU$2.01 loss per share (vs AU$1.73 loss in 1H 2022)

Anteris Technologies Ltd Announces DurAVR THV Demonstrates Exceptional Results in Second Valve-in-Valve Case

Anteris Technologies Announces First Successful Implantation of Duravr™ Thv in A Valve-In-Valve Procedure

Recent updates

Anteris Technologies Ltd, Annual General Meeting, May 29, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 40 million.

First half 2023 earnings released: AU$2.01 loss per share (vs AU$1.73 loss in 1H 2022)

Anteris Technologies Ltd Announces DurAVR THV Demonstrates Exceptional Results in Second Valve-in-Valve Case

Anteris Technologies Announces First Successful Implantation of Duravr™ Thv in A Valve-In-Valve Procedure

Full year 2022 earnings released: AU$3.32 loss per share (vs AU$3.09 loss in FY 2021)

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 35.000016 million.

Anteris Technologies Ltd announced that it expects to receive AUD 50 million in funding from Yorkville Advisors Global LP

Anteris Technologies Ltd Announces 12 Month Results for Anteris DurAVRTM Transcatheter Heart Valve Aortic Stenosis First in Human Study

Anteris Technologies Ltd Announces Formal Results of A Comparative Study to Investigate Aortic Flow Physiology by Cardiac MRI (cMRI) in Five Patients Who Received A DurAVR Transcatheter Aortic Valve (First- In-Human)

Anteris Technologies Ltd Announces Results Demonstrating Restoration of Normal Pre-Disease Flow

Anteris Technologies Announces Presentation of First-In-Human Data for its Novel TAVR Product, DurAVR™ at the 2022 Annual TCT Congress in Boston

First half 2022 earnings released: EPS: AU$0 (vs AU$1.58 loss in 1H 2021)

Dr. Martin Leon, MD Joins Global Medical Advisory Board of Anteris Technologies Ltd

Dr. Martin Leon, MD Joins Global Medical Advisory Board of Anteris Technologies Ltd

Anteris Technologies Ltd Provides Update on First In Human DurAVR THV Study

Anteris Announces 6 Month Follow Up of First Cohort of 5 Patients

Anteris Technologies Ltd Announces Successful Completion of Second First-In-Human Study

Anteris Technologies Ltd Announces Expansion of First in Human Trial

Anteris Technologies Ltd Appoints Dion Stub to Medical Advisory Board

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 27.6 million.

Anteris Technologies Ltd announced that it has received AUD 27.6 million in funding from Perceptive Advisors LLC

Anteris Technologies Ltd announced that it expects to receive AUD 27.6 million in funding from Perceptive Advisors LLC

Anteris Technologies Ltd, Annual General Meeting, May 19, 2022

Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) cancelled the acquisition of Anteris Technologies Ltd (ASX:AVR).

Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) signed a non-binding letter of intent to acquire Anteris Technologies Ltd (ASX:AVR).

Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) signed a non-binding letter of intent to acquire Anteris Technologies Ltd (ASX:AVR).

Anteris Technologies Ltd Reports Successful Interim Results for the First-In-Human Trial

Anteris Technologies Ltd Reports New Patent Application for ADAPT

Independent Chairman of the Board exercised options to buy AU$58k worth of stock.

First half 2021 earnings released: AU$1.58 loss per share (vs AU$1.01 loss in 1H 2020)

Anteris Technologies Ltd announced that it has received AUD 9 million in funding

Increases to CEO Compensation Might Be Put On Hold For Now at Anteris Technologies Ltd (ASX:AVR)

Anteris Technologies Ltd Announces Successful Completion of Proof of Concept (Poc) Animal Study

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.327895 million.

Anteris Technologies Ltd announced that it expects to receive AUD 2.327895 million in funding

Increases to Anteris Technologies Ltd's (ASX:AVR) CEO Compensation Might Cool off for now

Anteris Technologies Ltd, Annual General Meeting, May 14, 2021

New 90-day high: AU$5.52

Does Anteris Technologies' (ASX:AVR) CEO Salary Compare Well With The Performance Of The Company?

Full year 2020 earnings released

Anteris Technologies Ltd, Annual General Meeting, May 14, 2021

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.171499 million.

New 90-day high: AU$4.30

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.068135 million.

Anteris Technologies Announces Resignation of Yanheng Wu as A Non-Executive Director on the Board

Anteris Technologies Ltd (ASX:AVR) Insiders Have Been Selling

New 90-day low: AU$3.50

Anteris Technologies Ltd Reports Interim Results from Anti-Calcification Study

Anteris Technologies Limited Announces DurAVR Valve Patient Outcomes

First half earnings released

New 90-day low - AU$4.30